Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer
NCT07677566Phase 4Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jul 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
A Phase 4 trial of lutetium lu 177 vipivotide tetraxetan, darolutamide in prostate cancer (PCa), sponsored by Nanjing Drum-Tower Hospital. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetandarolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07677566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07677566.